Literature DB >> 16706820

A pilot study to evaluate a new combination therapy for gastric ulcer: Helicobacter pylori eradication therapy followed by gastroprotective treatment with rebamipide.

Akira Terano1, Tetsuo Arakawa, Toshiro Sugiyama, Toshikazu Yoshikawa, Ken Haruma, Masahiro Asaka, Tooru Shimosegawa, Nobuhiro Sakaki, Hiromasa Ishii, Choitsu Sakamoto, Shin-Ichi Takahashi, Yoshikazu Kinoshita, Toshio Fujioka, Kenzo Kobayashi.   

Abstract

BACKGROUND AND AIM: Controversies remain over the need for antiulcer treatment following 1-week eradication triple therapy for Helicobacter pylori-positive peptic ulcers. The usefulness of combination therapy for gastric ulcers in Japanese patients, which consists of H. pylori eradication followed by gastroprotective therapy with rebamipide, was therefore evaluated.
METHODS: The study was conducted in 52 H. pylori-positive patients with an endoscopically-proven open gastric ulcer. All patients received 1-week triple therapy (lansoprazole, amoxicillin and clarithromycin) followed by 7-week rebamipide therapy. After completion of the combination therapy, all patients underwent evaluation of ulcer healing by endoscopy, gastric ulcer symptoms and H. pylori eradication by rapid urease test and (13)C-urea breath test.
RESULTS: The ulcer healing rates were 85.7% (36/42) at 8 weeks, 83.3% (30/36) in eradicated patients and 100% (6/6) in non-eradicated patients. The overall gastrointestinal symptom-free rate improved from 19.0% at baseline to 88.1% at 8 weeks. H. pylori was effectively eradicated in 85.7% (36/42) of patients.
CONCLUSIONS: The results suggested that the combination therapy for open gastric ulcer was safe, well-tolerated and effective. However, data from a double-blind placebo-controlled study is necessary to confirm these findings.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16706820     DOI: 10.1111/j.1440-1746.2005.04191.x

Source DB:  PubMed          Journal:  J Gastroenterol Hepatol        ISSN: 0815-9319            Impact factor:   4.029


  4 in total

Review 1.  15th anniversary of rebamipide: looking ahead to the new mechanisms and new applications.

Authors:  Tetsuo Arakawa; Kazuhide Higuchi; Yasuhiro Fujiwara; Toshio Watanabe; Kazunari Tominaga; Eiji Sasaki; Nobuhide Oshitani; Toshikazu Yoshikawa; Andrzej S Tarnawski
Journal:  Dig Dis Sci       Date:  2005-10       Impact factor: 3.199

2.  Anti-inflammatory effects of rebamipide according to Helicobacter pylori status in patients with chronic erosive gastritis: a randomized sucralfate-controlled multicenter trial in China-STARS study.

Authors:  Yiqi Du; Zhaoshen Li; Xianbao Zhan; Jie Chen; Jun Gao; Yanfang Gong; Jianlin Ren; Liping He; Zhijian Zhang; Xiaozhong Guo; Jianshen Wu; Zibin Tian; Ruihua Shi; Bo Jiang; Dianchun Fang; Youming Li
Journal:  Dig Dis Sci       Date:  2008-02-21       Impact factor: 3.199

3.  Rebamipide, a gastro-protective and anti-inflammatory drug, promotes gastric ulcer healing following eradication therapy for Helicobacter pylori in a Japanese population: a randomized, double-blind, placebo-controlled trial.

Authors:  Akira Terano; Tetsuo Arakawa; Toshiro Sugiyama; Hidekazu Suzuki; Takashi Joh; Toshikazu Yoshikawa; Kazuhide Higuchi; Ken Haruma; Kazunari Murakami; Kenzo Kobayashi
Journal:  J Gastroenterol       Date:  2007-08-24       Impact factor: 7.527

Review 4.  Quality of healing of gastric ulcers: Natural products beyond acid suppression.

Authors:  Napapan Kangwan; Jong-Min Park; Eun-Hee Kim; Ki Baik Hahm
Journal:  World J Gastrointest Pathophysiol       Date:  2014-02-15
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.